Drug Combination Details
| General Information of the Combination (ID: C40680) | |||||
|---|---|---|---|---|---|
| Name | Gamma tocotrienol NP Info | + | Atorvastatin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Peritoneal cancer
[ICD-11: 2C51]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Inhibition | Mevalonate pathway | ||||
| In-vitro Model | NCI-H2052 | CVCL_1518 | Pleural sarcomatoid mesothelioma | Homo sapiens | ||
| NCI-H28 | CVCL_1555 | Pleural sarcomatoid mesothelioma | Homo sapiens | |||
| NCI-H2452 | CVCL_1553 | Pleural biphasic mesothelioma | Homo sapiens | |||
| MSTO-211H | CVCL_1430 | Pleural biphasic mesothelioma | Homo sapiens | |||
| Experimental
Result(s) |
Statin + Gamma-T3 combinations induced greater cell growth inhibition more than each single treatment via inhibition of mevalonate pathway, a well-known target of both Gamma-T3 and statins. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic effect of combined treatment with gamma-tocotrienol and statin on human malignant mesothelioma cells. Cancer Lett. 2013 Oct 1;339(1):116-27. | |||
